Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication
Abstract
Aim: To compare health-related quality of life (HRQoL) descriptions and utility scores in newly diagnosed peripheral arterial disease (PAD) patients, using two most widely used instruments, EuroQol 5D (EQ-5D) and Medical Outcome Study 36-item Short-Form Health Status Survey (SF-36). Methods: Patients’ self-assessment of HRQoL was measured by the Dutch versions of the EQ-5D and SF-36 in the 204 patients. Results: Mean utility scores ranged from 0.675 for Short-Form Six-Dimension, 0.648 for the EQ-5D UK tariff and 0.715 for the Dutch EQ-5D tariff. A moderate correlation between the utility scores was found due to different valuation techniques of these instruments. Conclusion: Both instruments have clinical validity for use in the PAD and can be used alongside each other to provide a holistic assessment of the HRQoL. Before using these two instruments interchangeably for utility score calculations and healthcare resource allocation, a thorough sensitivity analysis is necessary to explore the robustness of the value argument based on these utility scores.
Formats available
You can view the full content in the following formats:
References
1.
Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286(11), 1317–1324 (2001).
2.
McDermott MM, Liu K, Greenland P et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 292(4), 453–461 (2004).
3.
Belch JJ, Topol EJ, Agnelli G et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch. Intern. Med. 163(8), 884–892 (2003).
4.
NICE. Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence, London, UK, 1–93 (2013).
5.
Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Brit. Med. Bull. 96(1), 5–21 (2010).
6.
Drummond MF, Sculpher M, Torrance GW, O’Brien B, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, NY, USA (2005).
7.
College voor zorgverzekeringen D, the Netherlands. Guidelines for pharmacoeconomic research, updated version (2006). www.ispor.org/peguidelines/source/HTAGuidelinesNLupdated2006.pdf
8.
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21(2), 271–292 (2002).
9.
Brooks R. EuroQol: the current state of play. Health Pol. 37(1), 53–72 (1996).
10.
Whitehurst DGT, Bryan S, Lewis M. Systematic review and empirical comparison of contemporaneous EQ-5D and SF-6D group mean scores. Med. Decis. Making 31(6), E34–E44 (2011).
11.
Joore M, Brunenberg D, Nelemans P et al. The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies. Value Health 13(2), 222–229 (2010).
12.
Mazari FAK, Carradice D, Rahman MNAA et al. An analysis of relationship between quality of life indices and clinical improvement following intervention in patients with intermittent claudication due to femoropopliteal disease. J. Vasc. Surg. 52(1), 77–84 (2010).
13.
Mehta T, Venkata Subramaniam A, Chetter I, McCollum P. Assessing the validity and responsiveness of disease-specific quality of life instruments in intermittent claudication. Eur. J. Vasc. Endovasc. Surg. 31(1), 46–52 (2006).
14.
Hicken GJ, Lossing AG, Ameli FM. Assessment of generic health-related quality of life in patients with intermittent claudication. Eur. J. Vasc. Endovasc. Surg. 20(4), 336–341 (2000).
15.
Nicolaï SPA, Teijink JAW, Prins MH. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J. Vasc. Surg. 52(2), 348–355 (2010).
16.
Regensteiner JG, Hiatt WR, Coll JR et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) program. Vasc. Med. 13(1), 15–24 (2008).
17.
Dumville JC, Lee AJ, Smith FB, Fowkes FGR. The health-related quality of life of people with peripheral arterial disease in the community: the Edinburgh artery study. Br. J. Gen. Pract. 54(508), 826–831 (2004).
18.
Maksimovic M, Vlajinac H, Marinkovic J, Kocev N, Voskresenski T, Radak D. Health-related quality of life among patients with peripheral arterial disease. Angiology 65(6), 501–506 (2013).
19.
Tangelder MJ, McDonnel J, Van Busschbach JJ et al. Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) study group. J. Vasc. Surg. 29(5), 913–919 (1999).
20.
Klein WM, van der Graaf Y, Seegers J et al. Dutch iliac stent trial: long-term results in patients randomized for primary or selective stent placement. Radiology 238(2), 734–744 (2006).
21.
Gardner AW, Afaq A. Management of lower extremity peripheral arterial disease. J. Cardiopulm. Rehabil. Prev. 28(6), 349–357 (2008).
22.
Dolan P. Modeling valuations for EuroQol health states. Med. Care 35(11), 1095–1108 (1997).
23.
Dolan P, Roberts J. Modelling valuations for EQ-5D health states: an alternative model using differences in valuations. Med. Care 40(5), 442–446 (2002).
24.
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann. Med. 33(5), 337–343 (2001).
25.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30(6), 473–483 (1992).
26.
Aaronson NK, Muller M, Cohen PD et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J. Clin. Epidemiol. 51(11), 1055–1068 (1998).
27.
Fielding S, Fayers P, Ramsay C. Predicting missing quality of life data that were later recovered: an empirical comparison of approaches. Clin. Trials 7(4), 333–342 (2010).
28.
Sterne JA, White IR, Carlin JB et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338, b2393 (2009).
29.
Allison PD. Missing Data. SAGE (2001). https://pdfs.semanticscholar.org/58de/eac621923189c28cae06066652c218e126e4.pdf
30.
Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13(9), 873–884 (2004).
31.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476), 307–310 (1986).
32.
Liles DR, Kallen MA, Petersen LA, Bush RL. Quality of life and peripheral arterial disease. J. Surg. Res. 136(2), 294–301 (2006).
33.
Aquarius AE, Denollet J, Hamming JF, Van Berge Henegouwen DP, De Vries J. Type-D personality and ankle brachial index as predictors of impaired quality of life and depressive symptoms in peripheral arterial disease. Arch. Surg. 142(7), 662–667 (2007).
34.
Issa SM, Hoeks SE, Scholte op Reimer WJ et al. Health-related quality of life predicts long-term survival in patients with peripheral artery disease. Vasc. Med. 15(3), 163–169 (2010).
35.
Myers C, Wilks D. Comparison of EuroQol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual. Life Res. 8(1), 9–16 (1999).
36.
Chen J, Wong CK, McGhee SM, Pang PK, Yu WC. A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD). PLoS ONE 9(11), e112389 (2014).
37.
Ware JE, Snow KK, Kosinski M, Gandek B. Institute NEMCHH. SF-36 Health Survey: Manual and Interpretation Guide. The Health Institute, New England Medical Center, MA, USA (1993).
38.
Weinberger M, Samsa GP, Hanlon JT et al. An evaluation of a brief health status measure in elderly veterans. J. Am. Geriatr. Soc. 39(7), 691–694 (1991).
39.
Gerard K, Nicholson T, Mullee M, Mehta R, Roderick P. EQ-5D versus SF-6D in an older, chronically ill patient group. Appl. Health Econ. Health Pol. 3(2), 91–102 (2004).
40.
Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual. Life Outcomes 12(1), 74 (2014).
41.
Sach TH, Barton GR, Jenkinson C, Doherty M, Avery AJ, Muir KR. Comparing cost-utility estimates: does the choice of EQ-5D or SF-6D matter? Med. Care 47(8), 889–894 (2009).
42.
Kopec JA, Williams JI, To T, Austin PC. Cross-cultural comparisons of health status in Canada using the Health Utilities Index. Ethn. Health 6(1), 41–50 (2001).
Information & Authors
Information
Published In
Copyright
© 2018 Future Medicine Ltd.
History
Received: 25 April 2017
Accepted: 9 January 2018
Published online: 1 June 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2017-0029
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Areerut Leelathanalerk, Nuttakunlaya Piankarnka, Pornchanok Srimongkon, Suratchada Chanasopon, Panumart Phumart, Pawich Paktipat, Kritsanee Saramunee, Wiraphol Phimarn, Quality of life and utility of patients with peripheral artery disease (PAD): a systematic review and meta-analysis, Scientific Reports, 10.1038/s41598-024-80387-1, 14, 1, (2024).
- Emma Alicia MacLean, Ethan Joel Fogarty, Benjamin James Peterson, Shirley Xu, Nicholas Blair Giacomantonio, Peripheral Arterial Disease in Nova Scotia: Increased Prevalence, Low Public Awareness, and Poor Edinburgh Claudication Questionnaire Sensitivity, CJC Open, 10.1016/j.cjco.2024.07.003, 6, 10, (1210-1219), (2024).
- Jacquelyn B. Kercheval, Dennis I. Narcisse, Maggie Nguyen, Sunil V. Rao, J. Antonio Gutierrez, Nicholas J. Leeper, David J. Maron, Fatima Rodriguez, Adrian F. Hernandez, Kenneth W. Mahaffey, Svati H. Shah, Rajesh V. Swaminathan, Characterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health study, American Heart Journal, 10.1016/j.ahj.2024.06.010, 275, (183-190), (2024).
- Raza Alikhan, May Nour, Masahiro Yasaka, Richard Ofori-Asenso, Stina Axelsson-Chéramy, Hungta Chen, Vinay Seghal, Shoji Yokobori, Bruce Koch, Andreas Tiede, Brooks D. Cash, Marc Maegele, Adam J. Singer, Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor–associated major bleeds, Thrombosis Research, 10.1016/j.thromres.2024.109046, 240, (109046), (2024).
- Emilien C.J. Wegerif, Çağdaş Ünlü, Manon I. Generaal, Rutger M. van den Bor, Peter M. van de Ven, Michiel L. Bots, Gert J. de Borst, Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylic acid) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty (CLEAR-PATH), American Heart Journal, 10.1016/j.ahj.2024.04.001, 273, (121-129), (2024).
- Oleh Yakovenko, Serhii Soloviov, Mykhailo Smetiukh, Oleksandr Khanin, Eduard Khodosh, Yaroslav Dziublyk, Nataliia Surtaieva, Development and Approval of a Multidimensional Model of the Clinical Effectiveness of Treatment Technologies for Patients With a Mild COVID-19 Associated With Comorbidities, Innovative Biosystems and Bioengineering, 10.20535/ibb.2024.8.1.299055, 8, 1, (19-36), (2024).
- Bruce Guthrie, Gabriel Rogers, Shona Livingstone, Daniel R Morales, Peter Donnan, Sarah Davis, Ji Hee Youn, Rob Hainsworth, Alexander Thompson, Katherine Payne, The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis, Health and Social Care Delivery Research, 10.3310/KLTR7714, (1-275), (2024).
- Rob Hainsworth, Alexander J. Thompson, Bruce Guthrie, Katherine Payne, Gabriel Rogers, International Systematic Review of Utility Values Associated with Cardiovascular Disease and Reflections on Selecting Evidence for a UK Decision-Analytic Model, Medical Decision Making, 10.1177/0272989X231214782, 44, 2, (217-234), (2024).
- R. Trybulski, G. Biolik, W. Kuczmik, N. Ivasyk, O. Tyravska, Application of deep oscillation therapy in the treatment of peripheral arterial diseases, Medicni perspektivi, 10.26641/2307-0404.2023.3.289207, 28, 3, (116-127), (2023).
- Vojtěch Kamenský, Vladimír Rogalewicz, Ondřej Gajdoš, Gleb Donin, Discrete Event Simulation Model for Cost-Effectiveness Evaluation of Screening for Asymptomatic Patients with Lower Extremity Arterial Disease, International Journal of Environmental Research and Public Health, 10.3390/ijerph191811792, 19, 18, (11792), (2022).